| Serial Number | 79397452 |
| Word Mark | GENE COMPANY |
| Filing Date | Thursday, March 14, 2024 |
| Status | 661 - RESPONSE AFTER NON-FINAL ACTION - ENTERED |
| Status Date | Monday, March 31, 2025 |
| Registration Number | 0000000 |
| Registration Date | NOT AVAILABLE |
| Mark Drawing | 3 - Illustration: Drawing or design which also includes word(s) / letter(s) / number(s) |
| Published for Opposition Date | NOT AVAILABLE |
| Goods and Services | Custom manufacture of pharmaceutical products including manufacture of pharmaceutical preparations containing RNA, nucleic acids, protein nanoparticles; providing information in the field of custom manufacture of pharmaceuticals |
| Description of Mark | The mark consists of a stylized horizontal DNA helix with the stylized wording "GENE" to the right with the "G" partially superimposed over the helix. The stylized word "COMPANY" appears below both the helix and "GENE". |
| Goods and Services | Diagnostic medical, biological, and pharmaceutical preparations for SARS, Flu, MRSA, Dengue, COPD, Idiopathic pulmonary fibrosis, liver failure, liver cancer, NASH, Stroke, Pancreatic cancer, oral squamous cell cancer, Acute myloid leukemia (AML), skin burn, skin scarring, skin aging, eye diseases such as vitreoretinal eye disease, and Macular degeneration, diabetes, obesity for medical laboratory use; vaccines; vaccine adjuvants; DIAGNOSTIC medical, biological, and pharmaceutical preparations for SARS, Flu, MRSA, Dengue, COPD, Idiopathic pulmonary fibrosis, liver failure, liver cancer, NASH, Stroke, Pancreatic cancer, oral squamous cell cancer, Acute myloid leukemia (AML), skin burn, skin scarring, skin aging, eye diseases such as vitreoretinal eye disease, and Macular degeneration, diabetes, obesity for medical use, namely, preparations containing novel RNA nanoparticle technologies; nanoparticle formulations for pharmaceutical, medical or medical diagnostic purposes, namely, RNA packaged lipid and extravesicular nanoparticles; backbone modified conjugated RNAs, drug delivery agents for medical use consisting of RNA nanoparticle formulations that facilitate delivery of a wide range of pharmaceuticals; pharmaceutical preparations comprising drug delivery agents based on RNA nanoparticle formulations; pharmaceutical preparations, namely, RNA and delivery agents comprised of nanoparticle carriers and polymers for the delivery of RNA to human cells |
| Goods and Services | Chemical, biological, and bacteriological preparations, other than for medical or veterinary use, for scientific and research use, or for the manufacture of pharmaceuticals; chemical, biological, and bacteriological preparations for scientific and research use, or for the manufacture of pharmaceuticals, namely, preparations containing RNA nanoparticle technologies; RNA nanoparticles, namely, RNA packaged lipid nanoparticles, RNA packaged cell derived extracellular vesicles, chemically modified RNAs capable of naked delivery for scientific, laboratory or medical research use |
| NOT AVAILABLE | GENE COMPANY |
| Goods and Services | Pharmaceutical research and development; medical research services; biotechnology research; scientific research for medical purposes; design and development of medical technology, namely, design and testing for new product development; design, engineering, research, and development services in the field of novel RNA nanoparticle technologies for medical and scientific applications; providing medical and scientific research in the fields of pharmaceuticals and vaccines |
| International Class | 001 - Chemicals used in industry, science and photography, as well as in agriculture, horticulture and forestry; unprocessed artificial resins; unprocessed plastics; manures; fire extinguishing compositions; tempering and soldering preparations; chemical substances for preserving foodstuffs; tanning substances; adhesives used in industry. |
| US Class Codes | 001, 005, 006, 010, 026, 046 |
| Class Status Code | 6 - Active |
| Class Status Date | Thursday, June 13, 2024 |
| Primary Code | 001 |
| First Use Anywhere Date | NOT AVAILABLE |
| First Use In Commerce Date | NOT AVAILABLE |
| International Class | 005 - Pharmaceutical and veterinary preparations; sanitary preparations for medical purposes; dietetic substances adapted for medical use, food for babies; plasters, materials for dressings; material for stopping teeth, dental wax; disinfectants; preparations for destroying vermin; fungicides, herbicides. |
| US Class Codes | 005, 006, 018, 044, 046, 051, 052 |
| Class Status Code | 6 - Active |
| Class Status Date | Thursday, June 13, 2024 |
| Primary Code | 005 |
| First Use Anywhere Date | NOT AVAILABLE |
| First Use In Commerce Date | NOT AVAILABLE |
| International Class | 040 - Treatment of materials. |
| US Class Codes | 100, 103, 106 |
| Class Status Code | 6 - Active |
| Class Status Date | Thursday, June 13, 2024 |
| Primary Code | 040 |
| First Use Anywhere Date | NOT AVAILABLE |
| First Use In Commerce Date | NOT AVAILABLE |
| International Class | 042 - Scientific and technological services and research and design relating thereto; industrial analysis and research services; design and development of computer hardware and software. |
| US Class Codes | 100, 101 |
| Class Status Code | 6 - Active |
| Class Status Date | Thursday, June 13, 2024 |
| Primary Code | 042 |
| First Use Anywhere Date | NOT AVAILABLE |
| First Use In Commerce Date | NOT AVAILABLE |
| Party Name | Gene Company Pty Ltd |
| Party Type | 10 - Original Applicant |
| Legal Entity Type | 99 - Other |
| Address | AU |
| Event Date | Event Description |
| Thursday, June 13, 2024 | SN ASSIGNED FOR SECT 66A APPL FROM IB |
| Thursday, June 20, 2024 | NEW APPLICATION OFFICE SUPPLIED DATA ENTERED |
| Thursday, June 20, 2024 | APPLICATION FILING RECEIPT MAILED |
| Tuesday, September 24, 2024 | ASSIGNED TO EXAMINER |
| Wednesday, September 25, 2024 | NON-FINAL ACTION WRITTEN |
| Monday, September 30, 2024 | NON-FINAL ACTION MAILED - REFUSAL SENT TO IB |
| Monday, September 30, 2024 | REFUSAL PROCESSED BY MPU |
| Saturday, October 19, 2024 | REFUSAL PROCESSED BY IB |
| Monday, March 31, 2025 | CORRESPONDENCE RECEIVED IN LAW OFFICE |
| Monday, March 31, 2025 | TEAS RESPONSE TO OFFICE ACTION RECEIVED |
| Monday, March 31, 2025 | TEAS/EMAIL CORRESPONDENCE ENTERED |
| Thursday, September 26, 2024 | NON-FINAL ACTION (IB REFUSAL) PREPARED FOR REVIEW |